Search company, investor...

Stryker - Juvenile Tumour System


Acquired Unit | Acquired

About Stryker - Juvenile Tumour System

On June 13th, 2022, Stryker - Juvenile Tumour System was acquired by Onkos Surgical. Terms of the transaction were not disclosed. Stryker (NYSE: SYK) is a medical technology company that offers a diverse array of products and services in Orthopedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.

Headquarters Location

2825 Airview Blvd

Kalamazoo, Michigan, 49002,

United States


Missing: Stryker - Juvenile Tumour System's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stryker - Juvenile Tumour System's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Stryker - Juvenile Tumour System Frequently Asked Questions (FAQ)

  • Where is Stryker - Juvenile Tumour System's headquarters?

    Stryker - Juvenile Tumour System's headquarters is located at 2825 Airview Blvd, Kalamazoo.

  • What is Stryker - Juvenile Tumour System's latest funding round?

    Stryker - Juvenile Tumour System's latest funding round is Acquired Unit.

  • Who are the investors of Stryker - Juvenile Tumour System?

    Investors of Stryker - Juvenile Tumour System include Onkos Surgical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.